期刊文献+

顶空气相色谱法测定比伐芦定原料药中三乙胺残留量 被引量:3

Determination of Residual Solvent Triethylamine in Bivarudin by Headspace GC
下载PDF
导出
摘要 建立了顶空气相色谱法测定比伐芦定中三乙胺的残留量.顶空进样毛细管气相色谱法,采用DB-1毛细管色谱柱,柱温100℃,载气为氮气,检测器为氢火焰检测器.在上述色谱条件下三乙胺峰形最佳,三乙胺在1.9~17.5 μg/mL浓度范围内,呈良好线性关系(r=0.9995);三乙胺回收率为101.2 %(RSD=0.5%);定量限为0.19 μg/mL,检测限为90 ng/mL.本方法准确可靠,简便灵敏,重现性好,可用于比伐芦定中三乙胺残留量的测定. A headspace gas chromatography method for determination of residual triethylamine in bivarudin was established. It was quantitatively determined by headspace gas chromatography on DB-1 capillary column with FID detector, nitrogen as the carries. The column temperature was 100 ~C. The peak shape of triethylamine is quite well. Triethylamine presented a good linear correlation in range of 1.9-17.5 μg/mL, the correlation coefficient is 0.9995. The recoveries of triethylamine was 101.2 % (RSD=0.5 %). The limit of quantification is 0.19 μg/mL. The detection limit is 90 ng/mL. This method is definite, reliable, and simple, and can be used for determination of residual triethylamine in bivarudin.
出处 《广东化工》 CAS 2014年第23期194-195,共2页 Guangdong Chemical Industry
基金 国家科技计划 国家"十二五"科技重大专项(No.2012ZX09202-101-014)
关键词 气相色谱法 比伐芦定 三乙胺 GC bivarudin triethylamine
  • 相关文献

参考文献9

二级参考文献18

  • 1侯杰,刘健,盛惊州,李家泰.国产克林霉素磷酸酯体外抗菌作用研究[J].中国抗生素杂志,1996,21(2):124-132. 被引量:20
  • 2雷建强,满国海,高春环.高效液相色谱法测定头孢替安的含量[J].黑龙江医药,2006,19(3):159-160. 被引量:7
  • 3中华人民共和国2010版药典(二部)[M].北京:化学工业出版社.
  • 4Mehran R,Pocock SJ,Stone GW,et al.Associations of major bleeding andmyocardial infarction with the incidence and timing of mortality in patientspresenting with non-ST-elevation acute coronary syndromes:a risk model from theACUITY trial.Eur Heart J,2009;30:1457-1466.
  • 5Stone GW,Witzenbichler B5Guagliumi G,et al.Bivalirudin during primary PCI inacute myocardial infarction[J].N Engl J Med,2008;358(21):2218-2230.
  • 6Mehta SR,Tanguay JF,Eikelboom JW,et al0 Double-dose versus standard-doseclopidogrel and high-dose versus low-dose aspirin in individuals undergoingpercutaneous coronary intervention for acute coronary syndromes(CURRENT-OASIS 7):a randomized factorial trial.Lancet,2010;376:1233-1243.
  • 7Steg PG,James S,Harrington RA,et al.Ticagrelor versus clopidogrel in patientswith ST-elevation acute coronary syndromes intended for reperfusion with primarypercutaneous coronary intervention:a Platelet Inhibition and Patient Outcomes(PLATO)Trial subgroup analysis.Circulation,2010;122:2131-2141.
  • 8Mehran R,Lansky AJ,Witzenbichler B,et al.Bivalirudin in patients undergoingprimary angioplasty for acute myocardial infarction(HORIZONS-AMI):I-yearresults of a randomized controlled trial.Lancet,2009;374:1149-1159.
  • 9Kenji Goto,Alexandra J Lansky,Martin Fahy,et al.Predictors of outcomes inmedically treated patients with acute coronary syndromes after angiographictriage :an acute catheterization and urgent intervention triage strategy(ACUITY)substudy[J].Circulation,2010;121:853-862.
  • 10Jack Hirsh,Martin O’ Donnell,John W.Eikelboom.Beyond unfractionatedheparin and warfarin :current and future advances[J].Circulation,2007;116:552-560.

共引文献21

同被引文献27

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部